Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

Winston & Strawn LLP represented Clear Street, as underwriters in connection with the closing of Drugs Made in America Acquisition Corp.'s initial public offering. The offering consisted of 20,000,000 units, priced at $10.00 per unit, generating gross proceeds of $200,000,000 before deducting underwriting discounts and estimated offering expenses.

Each unit comprises one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols "DMAA" and "DMAAR," respectively.